Abstract:Abstract Head and neck squamous cell carcinoma (HNSCC) comprises 3% of all cancer cases worldwide. Despite intensive multimodal therapies, HNSCC patient outcomes remain heterogeneous with minimal improvements in survival. Utilization of fluid-based biomarkers for prognostication, risk stratification, and disease surveillance may improve patient outcomes by enabling more effective treatment decisions. Here, we describe the performance of comprehensive mutation and methylome analysis for highly sensitive detection of circulating tumor (ct)DNA in HNSCC plasma. To detect HNSCC-specific mutations and aberrant methylation in ctDNA, we conducted CAPP-Seq (CAncer Personalized Profiling by deep Sequencing) and cfMeDIP-seq (cell-free Methylated DNA ImmunoPrecipitation sequencing), respectively. For CAPP-Seq, we developed a HNSCC-specific hybrid capture panel and applied it to plasma DNA and peripheral blood leukocyte (PBL) genomic DNA from a cohort of HNSCC patients (n=32) and healthy controls (n=20). Single-nucleotide variants (SNVs) were identified by integrated digital error suppression (iDES). For cfMeDIP-seq, hypermethylated differentially methylated regions within regions of low PBL methylation were identified by DESeq2. A median of 3 mutations (range: 1-10) were detected by CAPP-Seq within plasma DNA of 20/32 (62.5%) HNSCC patients. Mean mutant allele frequency ranged from 0.1–5% (median: 0.92%) and correlated with tumor stage. Among these 20 patients, cfMeDIP-seq identified 860 DMRs that were enriched (hypermethylated) in HNSCC plasma DNA compared with healthy controls. These hypermethylated DMRs (hyper-DMRs) were over-represented by CpG islands and gene promoters and showed significant overlap with HNSCC-specific methylated regions in TCGA. When applied to all 32 HNSCC patients, hyper-DMR abundance was positively correlated with mutation-based ctDNA abundance (R=0.87; p=1e−16). Hyper-DMRs were capable of accurate discrimination of HNSCC patients and healthy controls (AUC=0.85). The median DNA fragment size within these hyperDMRs was lower in HNSCC patients compared to healthy controls—a characteristic of ctDNA described in previous studies—and correlated with both hyperDMR-based and mutation-based ctDNA abundance. We have conducted the first comparative analysis of genetic and epigenetic profiling approaches for ctDNA detection in HNSCC. Both CAPP-Seq and cfMeDIP-seq have the potential to detect ctDNA in patient plasma without prior knowledge of patient-specific tumor aberrations. With CAPP-seq, ctDNA was detectable at levels as low as 0.1%. Plasma methylome profiling using cfMeDIP-seq revealed hyper-DMRs with tumor-related features and that correlated with mutation-based ctDNA abundance. Future analysis will validate patient-specific mutations and methylation signals in tumor tissue and in longitudinally collected samples from this cohort. This abstract is also being presented as Poster B47. Citation Format: Justin M. Burgener, Jinfeng Zou, Zhen Zhao, Shu Y. Shen, Daniel D. De Carvalho, Scott V. Bratman. Comprehensive detection of ctDNA in localized head and neck cancer by genome- and methylome-based analysis [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr PR13.

Cell-free DNA Hypermethylated Genes May Have a Limited Role in Cancer Screening but a Potential Role in Risk Assessment of Head and Neck Cancer.

Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine

Abstract LB103: Cell-free DNA methylation as a noninvasive prognostic biomarker in hepatocellular carcinoma

An aberrant DNA methylation signature for predicting the prognosis of head and neck squamous cell carcinoma

Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy

Evaluation Of Promoter Hypermethylation Detection In Body Fluids As A Screening/Diagnosis Tool For Head And Neck Squamous Cell Carcinoma

DNA 5-Hydroxymethylcytosines from Cell-free Circulating DNA As Diagnostic Biomarkers for Human Cancers

Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients

Outlier Analysis Defines Zinc Finger Gene Family DNA Methylation in Tumors and Saliva of Head and Neck Cancer Patients

Unveiling targeted cell-free DNA methylation regions through paired methylome analysis of tumor and normal tissues

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers

Global DNA Methylation Level in Whole Blood as a Biomarker in Head and Neck Squamous Cell Carcinoma

Abstract 3454: Cell-free DNA methylation and fragmentomic signatures identify tissue damage and predict cancer risk

Abstract PR13: Comprehensive Detection of Ctdna in Localized Head and Neck Cancer by Genome- and Methylome-Based Analysis

Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma

Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer

DNA Methylation as a Diagnostic, Prognostic, and Predictive Biomarker in Head and Neck Cancer

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

High-sensitive Multi-Cancers Early Detection for 8 Cancer Types by Cell-Free DNA Targeted Methylation Sequencing: A Retrospective Cohort Study.

Gene methylation as a powerful biomarker for detection and screening of non-small cell lung cancer in blood